Current HIV research
A Randomized Controlled Trial Evaluating Virologic and Renal Outcomes After Switching from TDF+FTC or 3TC+EFV to TDF/3TC/DTG (TLD) Versus DTG+3TC in Virologically Suppressed Thai PWH - A Pilot Study.
Sathaporn Kanogtorn, Opass Putcharoen, Samadhi Patamatamkul
Published: 202510.2174/011570162X384022250910065252
Abstract
INTRODUCTION: Tenofovir disoproxil fumarate (TDF)/lamivudine (3TC)/dolutegravir (DTG) (TLD) is the preferred first-line therapy for all people living with HIV (PWH) per WHO 2019 and Thai HIV guidelines. This has prompted switches from TDF + FTC or 3T…
Preview only. Read the full abstract at the source